Colorectal Carcinoma Clinical Trial
— SMARTER CRCOfficial title:
Screening More Patients for CRC Through Adapting and Refining Targeted Evidence-Based Interventions in Rural Settings (SMARTER CRC)
Verified date | June 2024 |
Source | OHSU Knight Cancer Institute |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study collects information to provide a model for how to rapidly adapt and scale-up multilevel interventions through clinic-health plan partnerships to reduce the burden of colorectal cancer (CRC) on the United states population. This study may improve colorectal cancer screening rates, follow-up colonoscopy, and referral to care in rural Medicaid patients.
Status | Active, not recruiting |
Enrollment | 15510 |
Est. completion date | August 31, 2024 |
Est. primary completion date | August 31, 2024 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - CCOs/CCO STAFF: Serving a majority of counties that are predominantly rural based on 2010 Rural-Urban Commuting Area (RUCA) codes (codes 4-10) - CCOs/CCO STAFF: Willing to participate in data collection activities (e.g., producing claims data, interviews) - CLINICS: Clinics will be eligible for the cluster randomization if there are 30 or more patients eligible for screening - CLINICS: Are classified as rural according to RUCA (Codes 4-10) or Oregon Office of Rural Health designations - CLINICS: Are served by CCOs agreeing to participate in the project - CLINICS: Willing to implement the intervention into their clinic for the study - CLINIC STAFF/PROVIDERS: Employed as a clinician or ancillary staff member in a participating clinic - CLINIC STAFF/PROVIDERS: Willing to participate in data collection activities (e.g., interviews, observation, surveys) - PATIENTS: Attributed to participating clinic - PATIENTS: Are enrolled in Medicaid or dual eligible - PATIENTS: Eligible for colorectal cancer (CRC) screening - PATIENTS: For the subset of patients that will be invited to participate in key informant interviews, a 5th eligibility criteria is consented to participate - COMMUNITY OR REGIONAL/ORGANIZATIONAL PARTNERS: (Includes endoscopy providers, community-based outreach workers, or leaders from regional or national organizations who participate in the pilot, pragmatic trial, or scale-up study) - COMMUNITY OR REGIONAL/ORGANIZATIONAL PARTNERS: Involved in study activities (training, care delivery) - COMMUNITY OR REGIONAL/ORGANIZATIONAL PARTNERS: Willing to participate in data collection activities (e.g., trainings, interviews, surveys) - Elderly - Yes - we anticipate that a limited number of clinic and CCO staff, or community organization representatives may be elderly; we limit our patient recruitment to those aged 45-75 - Rural - Yes - Inner city - No - Low income - Yes - Disabled - Yes - Chronic care - Yes - End of life - Yes - This is possible, but we predict limited numbers because of the types of individuals we are recruiting: clinic and CCO staff, and patients who are not currently in hospice care - Minorities - Yes Exclusion Criteria: - CLINICS: Clinics are excluded if they have current or ongoing participating in other mailed fecal testing research projects in the Medicaid population - PATIENTS: Are current for screening - PATIENTS: Comorbid conditions that make patients poor candidates for screening based on clinical judgment (e.g., end-stage renal disease, enrollment in hospice) - PATIENTS: Are not an established patient or for other reasons documented by the clinics - All patients that we recruit will be at least 45 years of age or older |
Country | Name | City | State |
---|---|---|---|
United States | OHSU Knight Cancer Institute | Portland | Oregon |
Lead Sponsor | Collaborator |
---|---|
OHSU Knight Cancer Institute | National Cancer Institute (NCI), Oregon Health and Science University |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Likelihood of any colorectal cancer (CRC) screening (for study-eligible patients) | Will use claims and vendor data to determine whether or not the patient completed CRC screening (i.e., fecal testing, FIT-DNA, sigmoidoscopy, CT colonography, or colonoscopy). To assess effectiveness of CRC screening completion, will use the generalized form of hierarchical linear model (binomial distribution with logit link) to account for clustering of patients within clinics and the assignment to arm at the clinic level. | Primary outcome at 6 months following CCO eligible patient list pull date | |
Secondary | Completion of testing types (fecal testing, FIT-DNA, CT Colonography, Colonoscopy, Flex Sigmoidoscopy) and % completion | Will use claims and vendor data for calculating whether or not the patient completed each different type of screening. | Up to 12 months | |
Secondary | Rate of CRC screening among the study-eligible population (by clinic) | Will use claims and vendor data for calculating CRC screening rates in clinics. For each clinic, N completed CRC screening / N eligible | 6 months | |
Secondary | Time to screening from study-eligible patient list pull | Days from study-eligible patient list pull to return of FIT or completion of other screening modality (colonoscopy, flex, FIT-DNA). Number of days at individual level. | Up to 12 months | |
Secondary | FIT Results | Results of the completed FITs | 6 months | |
Secondary | Patient Navigation Trainings (Intervention group) | Clinic participation (i.e., attendance count and staff roles) in patient navigation training. | Up to 12 months | |
Secondary | Patient Navigation completed (Intervention group) | Patient navigation implemented = one or more live phone contact with the patient (binary at the individual level). | Up to 12 months | |
Secondary | Follow-up colonoscopy completion | The percentage of patients with abnormal FIT who completed follow-up colonoscopy. | Up to 12 months | |
Secondary | Time to colonoscopy from abnormal FIT result | Days from abnormal FIT result to completion of follow-up colonoscopy. Number of days at the individual level. | Up to 12 months | |
Secondary | Adenomas or cancers detected | Whether or not eligible patient had an adenoma or cancer detected. Binary at individual level. | Up to 12 months | |
Secondary | Adaptations to core program components made by payer or clinic | Key informant interviews and practice facilitator field notes based on the FRAME framework for tracking adaptations will be used to identify and qualitatively assess adaptations. | Up to 36 months | |
Secondary | Key Implementation Factors | Qualitative key informant interviews with patient, clinic, and payer stakeholders to identify implementation strategies and factors relevant to rural context. Guided by Consolidated Framework for Implementation Research (CFIR) and the Expert Recommendations for Implementing Change (ERIC) classification. | Up to 36 months | |
Secondary | Colonoscopy referral | For each clinic, the percent of patients who receive a referral to colonoscopy. Proportion at the clinic level. | Up to 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04444232 -
Cancer Communication Within Hispanic Social Networks
|
N/A | |
Recruiting |
NCT06233253 -
Online Mindfulness-Based Intervention to Decrease Pre-Procedural Anxiety Before a First-Time Screening Colonoscopy
|
N/A | |
Recruiting |
NCT05799820 -
QL1706 Monotherapy or in Combination With Bevacizumab and XELOX as First-line Treatment of Unresectable Advanced or Metastatic CRC
|
Phase 2 | |
Recruiting |
NCT04666727 -
Role of Diet on the Microbiome of the Digestive System
|
||
Recruiting |
NCT04767984 -
Testing Atorvastatin to Lower Colon Cancer Risk in Longstanding Ulcerative Colitis
|
Phase 2 | |
Recruiting |
NCT02376452 -
Phase II Study of 2-weekly RAILIRI Versus FOLFIRI as Second-line Treatment in Advanced Colorectal Cancer Patients
|
Phase 2 | |
Completed |
NCT02254486 -
Multicenter Randomized Parallel Group Phase III Study Comparing the Bowel Cleansing Efficacy, Safety and Tolerability of NER1006 Versus Trisulfate Solution Using 2-Day Split-Dosing Regimen in Adults
|
Phase 3 | |
Completed |
NCT01486251 -
Assessment of Tumor Vascular Effects of Axitinib With Dynamic Ultrasonography in Patients With Metastatic Colorectal Cancer
|
N/A | |
Terminated |
NCT01233544 -
Radiofrequency Ablation Versus Stereotactic Radiotherapy in Colorectal Liver Metastases
|
Phase 3 | |
Recruiting |
NCT02073500 -
Peritoneal Surface Malignancies - Characterization, Models and Treatment Strategies
|
||
Completed |
NCT00704600 -
Nelfinavir, a Phase I/Phase II Rectal Cancer Study
|
Phase 1/Phase 2 | |
Completed |
NCT00485316 -
Laparoscopic Assisted Versus Open Resection for Colorectal Carcinoma
|
Phase 3 | |
Recruiting |
NCT04430738 -
Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers
|
Phase 1/Phase 2 | |
Terminated |
NCT02669914 -
MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors
|
Phase 2 | |
Completed |
NCT05022511 -
Three Birds With One Stone
|
N/A | |
Not yet recruiting |
NCT03969784 -
Microparticles in Peritoneal Carcinomatosis of Colorectal Origin
|
N/A | |
Completed |
NCT04607291 -
Health Service Intervention for the Improvement of Access and Adherence to Colorectal Cancer Screening
|
Phase 1 | |
Not yet recruiting |
NCT05630794 -
Testing ONC201 to Prevent Colorectal Cancer
|
Phase 1 | |
Terminated |
NCT05291988 -
A Multilevel Approach for Improvement in Screening of Colorectal Cancer in Rural Communities, The Screen to Save Trial
|
N/A | |
Suspended |
NCT04108481 -
Immunotherapy With Y90-RadioEmbolization for Metastatic Colorectal Cancer
|
Phase 1/Phase 2 |